Skip links

Pipeline powered by groundbreaking glyco targeting engine

GO Therapeutics’ platform is continually generating new solid tumor targets, feeding a growing pipeline of novel cancer immuno-therapies.

ANTIBODY PROGRAM

MODALITIES

INDICATIONS

Mucins

GO-2

TCB

Breast, Colon, Ovarian     

ANTIBODY PROGRAM

GO-2

MODALITIES

TCB

INDICATIONS

Breast, Colon, Ovarian     

GO-2D5

TCB

Pancreatic, CRC, Bile Duct, Breast, Ovarian

ANTIBODY PROGRAM

GO-2D5

MODALITIES

TCB

INDICATIONS

Pancreatic, CRC, Bile Duct, Breast, Ovarian

Receptor Proteins

GO-4C8

CAR-T

Colon, Head & Neck, Lung

ANTIBODY PROGRAM

GO-4C8

MODALITIES

CAR-T

INDICATIONS

Colon, Head & Neck, Lung

GO-14C9

TCB

Liver, Gastric, Esophageal, Colon

ANTIBODY PROGRAM

GO-14C9, GO-8H3

MODALITIES

CAR-T, TCB

INDICATIONS

Liver, Gastric, Esophageal, Colon

GO-8H3

CAR-T

GO-17A3

CAR-T, TCB

Sarcoma, Melanoma

ANTIBODY PROGRAM

GO-17A3

MODALITIES

CAR-T, TCB

INDICATIONS

Sarcoma, Melanoma

Lysomal

GO-3C7

ADC

Prostate, Uterus, Head & Neck, Adenocarcinoma

ANTIBODY PROGRAM

GO-3C7

MODALITIES

ADC

INDICATIONS

Prostate, Uterus, Head & Neck, Adenocarcinoma

ECM

GO-C15

Immunokine

Breast, Prostate, Bladder, Oral Squamous Cell Carcinoma, Head & Neck Squamous Cell Carcinoma, Colorectal, Lung

ANTIBODY PROGRAM

GO-C15

MODALITIES

Immunokine

INDICATIONS

Breast, Prostate, Bladder, Oral Squamous Cell Carcinoma, Head & Neck Squamous Cell Carcinoma, Colorectal, Lung